Chronic Kidney Disease

An increase in alpha-globin gene copy number was associated with a greater prevalence of chronic kidney disease and incidence of end-stage kidney disease in Black Americans, according to published data.

An analysis of data showed patients with chronic kidney disease and type 2 diabetes who were or were not prescribed mineralocorticoid receptor antagonists saw reductions in major adverse kidney outcomes after taking dapagliflozin.

For patients with stage 5 chronic kidney disease on hemodialysis, high-dose extended-release calcifediol was well tolerated and reduced intact parathyroid hormone levels, according to research presented at ASN Kidney Week.

The risk for cardiovascular events is higher for adults with type 2 diabetes who have chronic kidney disease or other risk factors, even without the presence of cardiovascular disease, according to data published in Diabetic Medicine.

In an evaluation of four phase 3 trials presented at ASN Kidney Week, vadadustat had a comparable treatment-emergent adverse event profile compared with that of darbepoetin alfa for patients with chronic kidney disease.

Low-dose sevelamer in combination with a calcium-based phosphorus binder may be used in resource-constrained countries as a second-line therapy for patients with hyperphosphatemia to minimize calcium loading.

Compared with placebo, daprodustat was well tolerated and significantly increased hemoglobin levels in patients with chronic kidney disease, according to research presented at ASN Kidney Week.

Medical centers that used team-based coaching interventions such as Aautomated surveillance reporting and a virtual learning collaborative saw reductions in AKI and chronic kidney disease, according to a speaker at ASN Kidney Week.

Experts from the fields of diabetes, cardiorenal and metabolic disease, and obesity will discuss new research and present practice recommendations at the 19th World Congress on Insulin Resistance, Diabetes and Cardiovascular Disease.

The proteomic characterization of patients with chronic kidney disease allows for more generating mechanism-based hypotheses that could assist in future drug targeting, according to a speaker at American Society of Nephrology Kidney Week.